LENZ Therapeutics (NASDAQ:LENZ) Announces Quarterly Earnings Results

LENZ Therapeutics (NASDAQ:LENZ) posted its earnings results on Tuesday. The company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.25), FiscalAI reports. The business had revenue of $1.59 million for the quarter, compared to analyst estimates of $3.09 million.

Here are the key takeaways from LENZ Therapeutics’ conference call:

• Product performs in the real world: Company reports LNZ100 (VIZZ) produces near-vision improvement within ~30 minutes and up to ~10 hours, with early patient feedback and clinical results translating into encouraging persistence.
• Early commercial traction: the company estimates >45,000 monthly packs sold and >10,000 prescribing eye‑care professionals, and says its top 1,000 prescribers are writing ~40% more scripts per doctor vs. a comparable point in the Vuity launch.
• Sampling-driven launch strategy is producing a stickier refill base but a more gradual ramp in new patient starts, so broader adoption depends on physician education and time to build the category.
• Commercial scale-up underway: sales force expanding from 88 to 117 reps and a national DTC campaign (Sarah Jessica Parker spokesperson) is driving website traffic ~5x baseline (up to 10x on activations), with the company expecting DTC effects on scripts to materialize over ~two quarters.
• Financial and regulatory runway: LENZ exited the quarter with approximately $292.3M cash, is debt‑free, reported Q4 product revenue of ~$1.6M and ~ $32M quarterly cash burn, plans to allocate ~75–80% of OpEx to sales & marketing, and is pursuing multiple ex‑U.S. filings with potential approvals in 2027.

LENZ Therapeutics Trading Up 0.4%

LENZ opened at $9.07 on Thursday. The firm’s 50 day simple moving average is $14.14 and its two-hundred day simple moving average is $24.40. The company has a market capitalization of $283.80 million, a PE ratio of -3.23 and a beta of 0.52. LENZ Therapeutics has a 1-year low of $8.85 and a 1-year high of $50.40.

Key Stories Impacting LENZ Therapeutics

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: Bank of America cut its price target from $35 to $29 but kept a “buy” rating, signaling continued analyst conviction in LENZ’s upside despite the reduction in target. Bank of America lowers PT to $29, keeps buy
• Positive Sentiment: Company reports and press coverage say the launch of LNZ100 exceeded expectations and could open a sizable market opportunity if uptake continues. This product news supports longer‑term revenue scenarios. LNZ100 launch story
• Positive Sentiment: LENZ outlined a 2026 acceleration strategy and expanded its VIZZ sales force to 117 reps, a commercial investment intended to drive growth and support the new product rollout. Sales force expansion article
• Neutral Sentiment: Management emphasized a strong cash position on the Q4 call, which reduces near‑term financing risk but doesn’t offset near‑term revenue weakness on its own. Earnings call highlights
• Neutral Sentiment: Reports show a reported “large increase” in short interest for March, but the published figures contain zeros/NaN and an apparent data error — monitor for corrected filings. (No reliable source link available)
• Negative Sentiment: Q4 results missed expectations: EPS of ($1.16) missed consensus and revenue of $1.59M fell well short of estimates; the miss triggered headlines that shares hit an all‑time low. These operating shortfalls are the primary near‑term catalyst weighing on the stock. MarketWatch: shares hit all-time low Earnings release/transcript

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of LENZ Therapeutics in a research note on Thursday, January 22nd. William Blair restated an “outperform” rating on shares of LENZ Therapeutics in a report on Tuesday, March 10th. Bank of America cut their target price on shares of LENZ Therapeutics from $35.00 to $29.00 and set a “buy” rating for the company in a research report on Wednesday. Wall Street Zen cut LENZ Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, HC Wainwright restated a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, LENZ Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $50.20.

Institutional Investors Weigh In On LENZ Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of LENZ. Creative Planning purchased a new position in LENZ Therapeutics during the second quarter valued at $412,000. JPMorgan Chase & Co. increased its position in LENZ Therapeutics by 28.7% in the second quarter. JPMorgan Chase & Co. now owns 10,361 shares of the company’s stock worth $304,000 after buying an additional 2,310 shares in the last quarter. Legal & General Group Plc raised its stake in shares of LENZ Therapeutics by 25.7% in the second quarter. Legal & General Group Plc now owns 10,989 shares of the company’s stock worth $322,000 after buying an additional 2,247 shares during the period. Rhumbline Advisers raised its stake in shares of LENZ Therapeutics by 35.6% in the second quarter. Rhumbline Advisers now owns 24,363 shares of the company’s stock worth $714,000 after buying an additional 6,396 shares during the period. Finally, Russell Investments Group Ltd. lifted its position in shares of LENZ Therapeutics by 1,105,675.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 44,231 shares of the company’s stock valued at $1,296,000 after buying an additional 44,227 shares in the last quarter. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.